Kanorskiĭ S G
Kardiologiia. 2013;53(10):89-95.
According to results of large clinical studies angiotensin II receptor blockers (ARB) and aliskiren do not lower risk of cardiovascular complications and mortality in wide spectrum of clinical conditions and are able to worsen renal outcomes. It is expedient to prefer inhibitors of angiotensin converting enzyme in particular perindopril over ARB in the treatment of patients with arterial hypertension taking into consideration differences in effect on mortality. Fixed perindopril/indapamide combination provides achievement of target arterial pressure in many patients with uncontrolled hypertension, has good tolerability, is metabolically neutral, and possesses high organoprotective properties.
根据大型临床研究结果，血管紧张素II受体阻滞剂（ARB）和阿利吉仑在广泛的临床情况下并不能降低心血管并发症和死亡率的风险，反而会使肾脏结局恶化。考虑到对死亡率影响的差异，在治疗动脉高血压患者时，优先选用血管紧张素转换酶抑制剂，特别是培哚普利，而非ARB。固定剂量的培哚普利/吲达帕胺组合能使许多血压控制不佳的患者达到目标动脉血压，耐受性良好，代谢中性，且具有高度的器官保护特性。
